In comparison to the synthetic modulators of NRF2, BT was observed to be equally potent or even better than t-BHQ/ML-385 in the overall reorientation of NRF2 and its regulators as well as causing sufficient cytotoxicity in lung cancer cells. The gene discussed is NFE2L2; the disease is lung carcinoma.